Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung Cancer
Titel:
Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung Cancer